Diligence memo · auto-generated · as of July 2, 2026
Prellis Biologics, Inc
Prellis Biologics, Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Prellis Biologics, Inc operates in Biotech / Pharma, based in Hayward.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Prellis Biologics, Inc has raised $47M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2021-07-01.
Most recent recorded round closed around 2022-06-22.
Valuation (modeled)modeled
Provath models Prellis Biologics, Inc at approximately $277M (range $35M–$731M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.05× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (105% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 4.0 yr ago; this sector typically re-raises about every 15 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 87% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 84% of those peers.
Closest niche peers: Carbon Biosciences, Inc., Slingshot Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Turn Biotechnologies, Inc..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.